Compiled by Black Book Research from VC PE and banking investors, the briefing ranks which AI-driven categories are converting pilots to scale and where capital rotation is expected to accelerate, ...
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...
In the rapidly evolving pharmaceutical landscape, drug discovery services have become a pivotal axis around which innovation, ...
The clinical laboratory services market is entering a phase of sustained expansion, fueled by evolving healthcare dynamics, ...
FORT LAUDERDALE, FL / ACCESS Newswire / October 20, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare ...
The New Standard for Business ContinuityEngineering for Continuity in Extreme WeatherBy: Oscar Infanzon, Design Engineer & ...
Lab Innovations, the UK’s largest trade show for the lab industry, taking place at the NEC, Birmingham, on October 29 and 30, ...
SOM Biotech, a clinical-stage company dedicated to the discovery and development of innovative therapies for rare central nervous system disorders, announces today that it has received the final ...
New safety, efficacy and pharmacokinetic results presented from dose escalation portion of the studyAnti-tumour activity observed across all dose levels and in various tumour indicationsNEWCASTLE, ...
Introduction: How China Pharmaceutical Distributors Shape Global TradeIn the past decade, China pharmaceutical distributors have moved from low-cost suppliers to strategic global partners in ...
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors ...
Early in my career, I was helping coordinate a Phase II oncology trial across multiple time zones. One site, located in Eastern Europe, kept falling behind. The issue wasn’t patient recruitment. It ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results